Clinical trialPhase 1Completed
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 8 April 2021
- Expected end
- 28 June 2024
- Enrollment
- 41 participants
- Sites
- 1
- Primary outcomes
- MTD; RP2D
- Sponsor
- Industry
- Results posted
- No
- Last update
- 29 April 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy